Seaport Therapeutics (NASDAQ:SPTX) Shares Down 5.2% – Here’s Why

Posted by Brian Himes on Aug 27th, 2026

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX – Get Free Report) were down 5.2% during trading on Thursday . The stock traded as low as $26.32 and last traded at $26.39. 72,304 shares changed hands during trading, a decline of 66% from the average daily volume of 210,000 shares. The stock had previously closed at $27.84.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. JonesTrading began coverage on shares of Seaport Therapeutics in a report on Wednesday. They set a “buy” rating and a $32.00 price target on the stock. UBS Group cut shares of Seaport Therapeutics to a “sell” rating in a report on Tuesday, June 9th. BNP Paribas Exane downgraded shares of Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Finally, Leerink Partners assumed coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.33.

View Our Latest Stock Report on SPTX

Seaport Therapeutics Stock Down 5.1%

The firm’s 50-day simple moving average is $21.53. The firm has a market capitalization of $1.41 billion and a P/E ratio of -2.18.

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). Equities analysts anticipate that Seaport Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert J. Hombach purchased 13,000 shares of Seaport Therapeutics stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the purchase, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Institutional Investors Weigh In On Seaport Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SPTX. TRV GP VI LLC bought a new stake in Seaport Therapeutics in the 2nd quarter worth approximately $44,769,742,000. Braidwell LP bought a new position in shares of Seaport Therapeutics during the 2nd quarter valued at $10,860,000. Alyeska Investment Group L.P. purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth $1,629,000. Finally, HighTower Advisors LLC purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth $362,000.

About Seaport Therapeutics

(Get Free Report)

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.